

## **About the author**

Disclaimer

## **EXECUTIVE SUMMARY**

Molecular diagnostic technologies

Healthcare-associated infections

Sexually transmitted HPVs

HIV and hepatitis viruses

Viral respiratory pathogens

Market outlook and forecasts

## **Molecular diagnostic technologies**

Summary

Role of molecular diagnostics in infectious diseases

Overview of nucleic acid testing (NAT)

Sample processing

Probe-based testing

Innovations in nucleic acid amplification technologies

PCR-based amplification technologies

Alternative amplification technologies

Automated platforms for NAT

Point-of-care real-time PCR testing systems

Microfluidics

Digital PCR

Innovations in nucleic acid microarrays

Development of microarray formats

Suspension bead and other 3D arrays

Innovations in next-generation sequencing

Innovations in mass spectrometry methods

Innovations in protein arrays

## **Healthcare-associated infections**

Summary

The challenge of drug-resistant pathogens

MRSA

Culture vs. nucleic acid tests

FDA-approved nucleic acid tests

Examples of technologies and products in development

Clostridium difficile

Traditional tests

FDA approved nucleic acid tests

Vancomycin-resistant enterococci (VRE)

Culture and nucleic acid tests

Bloodstream pathogens

- Blood culture
- Microorganisms found in blood cultures
- FDA-approved nucleic acid tests
- Amplification-based products in development
- Mass spectrometry-based products in development

### **Sexually transmitted HPVs**

- Summary
- HPV infections
- The HPV genome
- Screening for cervical cancer
- Analytical versus clinical sensitivity of HPV tests
- Genotyping HPV in clinical specimens
- Vaccination and implications for testing
- Products on the market and in development
- Target amplification techniques
  - Reverse line blot and linear array tests
  - Amplicor
  - PapilloCheck
  - Bead-based assays
  - Assays using real-time PCR amplification
- Signal amplification techniques
  - Hybrid Capture 2 assay (FDA-approved)
  - Cervista (FDA-approved)
- Detection of HPV mRNA
  - Nuclisens
  - Aptima HPV (FDA-approved)

### **HIV and hepatitis viruses**

- Summary
- Introduction
- HIV infections
  - Characteristics of HIV
  - HIV testing strategies
- HIV load testing
  - FDA-approved assays
  - Tests in development
  - Digital PCR approach
- Drug resistance testing
- HBV infections
  - Characteristics of HBV
  - HBV load testing
  - Drug resistance testing

- Detection of co-infecting HDV
- HCV infections
  - Characteristics of HCV
  - HCV load testing
  - Drug resistance and drug efficacy testing
- FDA-approved blood screening tests
- Occult HBV and HCV infections
  - HCV-RNA assays
  - HBV-DNA assays

## **Viral respiratory pathogens**

- Summary
- Introduction
- Important respiratory viruses
  - Influenza A/B viruses
  - Respiratory syncytial virus
  - Human parainfluenza virus
  - Adenovirus 1
  - Rhinovirus
- Emerging respiratory viruses
  - Avian influenza and influenza A swine flu
  - SARS-covirus and other human coronaviruses
  - Human metapneumovirus
  - Human bocavirus
- Multiplex respiratory virus panels
- Influenza virus panels
- Respiratory virus panels
  - Luminex's xTAG RVP
  - Qiagen's ResPlex II
  - EraGen Biosciences' MultiCode-PLx RVP
  - Comparison of xTAG, ResPlex II, and MultiCode-Plx
  - AutoGenomics' Infiniti System
  - Seegene's Seeplex RP Assay
  - Idaho's real-time PCR FilmArray
  - BD's real-time PCR Jaguar System
  - PrimerADx's quantitative PCR STAR technology
  - Abbott's PLEX-ID for pathogen discovery

## **Market outlook and forecasts**

- Summary
- Introduction
  - MDx opportunities in viral hemorrhagic fevers
  - MDx opportunities in other emerging pathogens

## Multiplexed MDx technology trends

- Microarrays and microfluidic devices

- Mass spectrometry

## Widening adoption of MDx tests

- Migration of MDx out of core labs

- Emergence of POC MDx platforms

## MDx market characteristics

- The global MDx market

- Changing competitive landscape

- Changing MDx regulation

- Changing reimbursement

## Forecasts for key MDx market sectors

- HAIs

- HPV

- HIV, HCV, and HBV

- Viral respiratory pathogens

## **Appendix**

- Scope

- Methodology

- Glossary/Abbreviations

- Bibliography/References

  - Journal references

  - Website references

- Additional information

## **TABLES**

Table: FDA–approved real–time PCR amplification systems

Table: FDA–approved automated platforms for nucleic acid testing

Table: FDA–approved microarray systems

Table: FDA approved MRSA screening tests

Table: FDA approved C. difficile and VRE tests

Table: FDA approved tests for bloodstream pathogens

Table: Nucleic acid tests for HPV detection and genotyping

Table: Nucleic acid tests for HPV detection and genotyping (continued)

Table: Nucleic acid tests for HPV detection and genotyping (continued)

Table: FDA approved HIV quantification and drug resistance assays

Table: FDA approved HBV and HCV quantitative assays

Table: FDA approved blood screening assays for HBV, HCV, and HIV

Table: FDA approved tests for viral respiratory pathogens

Table: FDA approved tests for viral respiratory pathogens (continued)

Table: Global MDx market forecasts by reviewed segment, 2010–15

Table: Viral hemorrhagic fevers and other emerging viruses

Table: Viral hemorrhagic fevers and other emerging viruses

Table: Viral hemorrhagic fevers and other emerging viruses

Table: Viral hemorrhagic fevers and other emerging viruses

## **FIGURES**

Figure: GeneXpert System for nucleic acid testing

Figure: The principle of digital PCR

Figure: Nucleic acid detection by suspension bead array

Figure: Real-time PCR digital microfluidics platform

Figure: Genotyping of microorganisms by PCR/ESI-mass spectrometry

Figure: PapilloCheck HPV microarray test

Figure: HPV assay with Invader technology

Figure: Digital PCR for viral load determination

Figure: FilmArray for diagnosis of respiratory infection

Figure: STAR technology for diagnosis of respiratory infection

Figure: Forecast growth in MDx market segments, 2010–15